{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:54:34Z","timestamp":1787018074425,"version":"build-2736575974"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2019,12,17]]},"abstract":"<jats:p>Following regulatory guidance set forth in 2008 by the US Food and Drug Administration for new drugs for type 2 diabetes mellitus, many large randomized, controlled trials have been conducted with the primary goal of assessing the safety of antihyperglycemic medications on the primary end point of major adverse cardiovascular events, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Heart failure (HF) was not specifically mentioned in the US Food and Drug Administration guidance and therefore it was not a focus of these studies when planned. Several trials subsequently showed the impact of antihyperglycemic drugs on HF outcomes, which were not originally specified as the primary end point of the trials. The most impressive finding has been the substantial and consistent risk reduction in HF hospitalization seen across 4 trials of sodium glucose cotransporter 2 inhibitors. However, to date, these results have not led to regulatory approval of any of these drugs for a HF indication or a recommendation for use by US HF guidelines. It is therefore important to explore to what extent persuasive treatment effects on nonprimary end points can be used to support regulatory claims and guideline recommendations. This topic was discussed by researchers, clinicians, industry sponsors, regulators, and representatives from professional societies, who convened on the US Food and Drug Administration campus on March 6, 2019. This report summarizes these discussions and the key takeaway messages from this meeting.<\/jats:p>","DOI":"10.1161\/circulationaha.119.042155","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T14:00:16Z","timestamp":1576504816000},"page":"2108-2118","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus"],"prefix":"10.1161","volume":"140","author":[{"given":"Javed","family":"Butler","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Center, Jackson (J.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center, Dallas, TX (M.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC (S.J.G., M.F., K.J.A., A.F.H.)."},{"name":"Division of Cardiology, Duke University School of Medicine, Durham, NC (S.J.G., A.F.H.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Fiuzat","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC (S.J.G., M.F., K.J.A., A.F.H.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Berlin-Brandenburg Center for Regenerative Therapies, Germany (S.D.A.)."},{"name":"Department of Cardiology, German Center for Cardiovascular Research partner site Berlin, Charite Universitatsmedizin Berlin (S.D.A.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Anstrom","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC (S.J.G., M.F., K.J.A., A.F.H.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Carson","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Department of Cardiology, Washington Veterans Affairs Medical Center (P.E.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren B.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Inova Heart and Vascular Institute, Falls Church, VA (L.B.C., C.M.O.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC (S.J.G., M.F., K.J.A., A.F.H.)."},{"name":"Division of Cardiology, Duke University School of Medicine, Durham, NC (S.J.G., A.F.H.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Cardiology Division, Massachusetts General Hospital and Baim Institute for Clinical Research, Boston (J.L.J.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariell","family":"Jessup","sequence":"additional","affiliation":[{"name":"American Heart Association, Dallas, TX (M.J.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita R.","family":"Kalyani","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD (R.R.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kaul","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center, Los Angeles, CA (S.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute, University of Missouri-Kansas City (M.K.)"},{"name":"The George Institute for Global Health, University of New South Wales, Sydney, Australia (M.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Lindenfeld","sequence":"additional","affiliation":[{"name":"Vanderbilt Heart and Vascular Institute, Nashville, TN (J.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"TIMI Study Group (M.S.S.), Brigham and Women\u2019s Hospital, Boston, MA."},{"name":"Division of Cardiovascular Medicine (M.S.S., S.D.S., M.V.), Brigham and Women\u2019s Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine (M.S.S., S.D.S., M.V.), Brigham and Women\u2019s Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Teerlink","sequence":"additional","affiliation":[{"name":"Section of Cardiology, San Francisco Veterans Affairs Medical Center, CA (J.R.T.)."},{"name":"School of Medicine, University of California, San Francisco (J.R.T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine (M.S.S., S.D.S., M.V.), Brigham and Women\u2019s Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clyde W.","family":"Yancy","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL (C.W.Y.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Stockbridge","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular and Renal Products, United States Food and Drug Administration, Silver Spring, MD (N.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Inova Heart and Vascular Institute, Falls Church, VA (L.B.C., C.M.O.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","unstructured":"Food and Drug Administration. Guidance for industry: diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 mellitus. 2008. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm071627.pdf. Accessed June 1 2017."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072761"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1971.03190220020005"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61514-1"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.20.joc50147"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-S009"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.09.020"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60953-3"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.933"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1432"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2019.01.006"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.3.699"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.4115"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci17-0052"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70031-2"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.01.047"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040130"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv728"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034222"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1183"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037599"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032099"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.0924"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.08.074"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.517"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.033502"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040057"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.5250"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1341"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.71"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.020729"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1323"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.12.034"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.04.005"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.111958"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32824-1"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038868"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.039996"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.05.016"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.01.012"},{"key":"e_1_3_2_50_2","first-page":"25","volume-title":"In: A Quick Guide to Clinical Trials","author":"Junod S","year":"2016","unstructured":"Junod, S. FDA and clinical drug trials: a short history. Davies, M, Kermani, F, eds. In: A Quick Guide to Clinical Trials. 2nd ed. Rockville, MD: Bioplan Inc; 2016:25\u201355.","edition":"2"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780100102"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1709701"},{"key":"e_1_3_2_53_2","unstructured":"Food and Drug Administration. Multiple endpoints in clinical trials: guidance for industry. 2017. https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm536750.pdf. Accessed April 8 2019."},{"key":"e_1_3_2_54_2","unstructured":"European Medicines Agency. Points to consider on multiplicity issues in clinical trials. 2002. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/points-consider-multiplicity-issues-clinical-trials_en.pdf. Accessed April 9 2019."},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199702203360801"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307013290101"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271003"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)04560-8"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271001"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042934"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-012-0467-8"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1231"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.119.042155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:06:39Z","timestamp":1715573199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.119.042155"}},"subtitle":["A Critical Evaluation of Clinical and Regulatory Issues"],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":63,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2019,12,17]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.119.042155"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.119.042155","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"assertion":[{"value":"2019-12-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}